(Q33408947)

26 July 2017

title

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors (English)

1 reference

26 July 2017

M Mita

1

1 reference

26 July 2017

M Gordon

2

1 reference

26 July 2017

N Rejeb

3

1 reference

26 July 2017

A Gianella-Borradori

4

1 reference

26 July 2017

V Jego

5

1 reference

26 July 2017

A Mita

6

1 reference

26 July 2017

J Sarantopoulos

7

1 reference

26 July 2017

K Sankhala

8

1 reference

26 July 2017

D Mendelson

9

1 reference

26 July 2017

publication date

6 July 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

9

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

215-224

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-013-0288-3

26 July 2017

exact match

0 references

cites work

Microtubule-binding natural products for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Chromosomal passengers and the (aurora) ABCs of mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Mitotic kinases as regulators of cell division and its checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0288-3

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23832397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-013-0288-3

1 reference

Dimensions Publication ID

26 July 2017

1047272018

0 references

1 reference